These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 29112482)
1. Regulating the advertising and promotion of stem cell therapies. von Tigerstrom B Regen Med; 2017 Oct; 12(7):815-826. PubMed ID: 29112482 [TBL] [Abstract][Full Text] [Related]
2. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action. Caulfield T; Murdoch B BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026 [TBL] [Abstract][Full Text] [Related]
3. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients. Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513 [TBL] [Abstract][Full Text] [Related]
4. Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics. Ghinea N; Munsie M; Rudge C; Stewart C Regen Med; 2020 Feb; 15(2):1361-1369. PubMed ID: 32228372 [TBL] [Abstract][Full Text] [Related]
5. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions. Turner L Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145 [TBL] [Abstract][Full Text] [Related]
6. [The advertising of medicinal products to the public in Poland--legislative, ethical, health and social concerns]. Cianciara D Przegl Epidemiol; 2004; 58(3):555-63. PubMed ID: 15730020 [TBL] [Abstract][Full Text] [Related]
8. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions. Ogbogu U; Du J; Koukio Y BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594 [TBL] [Abstract][Full Text] [Related]
9. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure? McLean AK; Stewart C; Kerridge I J Law Med; 2014 Sep; 22(1):65-89. PubMed ID: 25341320 [TBL] [Abstract][Full Text] [Related]
10. Paternalistic or protective? Freedom of expression and direct-to-consumer drug advertising policy in Canada. Gold JL Health Law Rev; 2003; 11(2):30-6. PubMed ID: 15706698 [No Abstract] [Full Text] [Related]
11. It's time to shine the light on direct-to-consumer advertising. Mackey TK; Liang BA Ann Fam Med; 2015; 13(1):82-5. PubMed ID: 25583897 [TBL] [Abstract][Full Text] [Related]
12. Problems associated with direct-to-consumer advertising (DTCA) of restricted, implantable medical devices: should the current regulatory approach be changed? Patsner B Food Drug Law J; 2009; 64(1):1-41. PubMed ID: 19998571 [TBL] [Abstract][Full Text] [Related]
13. Restrictions on the conduct of advertising of medicinal products in Poland and their violations. Czerw A; Marek EM Acta Pol Pharm; 2013; 70(4):769-76. PubMed ID: 23923402 [TBL] [Abstract][Full Text] [Related]
14. Legal overview of likely FDA regulation of Internet promotion. Scheineson MJ Food Drug Law J; 1996; 51(4):697-716. PubMed ID: 11797736 [No Abstract] [Full Text] [Related]
15. The dangers of unregulated stem-cell marketing. Mohammadi D Lancet; 2017 Oct; 390(10105):1823-1824. PubMed ID: 28870714 [No Abstract] [Full Text] [Related]
16. [Legal requirements on medical advertising using the example of Kinesio Taping]. Oehler T Dtsch Med Wochenschr; 2013 Nov; 138(45):2322-4. PubMed ID: 24163170 [No Abstract] [Full Text] [Related]
17. Marketing of unproven stem cell-based interventions: A call to action. Sipp D; Caulfield T; Kaye J; Barfoot J; Blackburn C; Chan S; De Luca M; Kent A; McCabe C; Munsie M; Sleeboom-Faulkner M; Sugarman J; van Zimmeren E; Zarzeczny A; Rasko JEJ Sci Transl Med; 2017 Jul; 9(397):. PubMed ID: 28679655 [TBL] [Abstract][Full Text] [Related]
18. The role of the Federal Trade Commission in advertising health products and services. Daynard M J Am Coll Dent; 2004; 71(2):24-6. PubMed ID: 15347100 [TBL] [Abstract][Full Text] [Related]